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Female sheep exposed to excess testosterone (T) in utero display symptoms
similar to those observed in women with polycystic ovarian syndrome (PCOS). Prenatal
T-treated ewes display masculinized sexual behavior and increased food-reward seeking
behavior. A neural substrate critical for these goal-directed behaviors is the dopaminergic
system in the ventral tegmental area. We have recently shown that in adult ewes
dopamine expression in the VTA is increased by prenatal T exposure. In this thesis, I
tested the hypothesis that alterations of the VTA dopamine system by prenatal-T are
caused via activation of androgen (AR) and/or insulin receptors (IR). Analysis of
immunohistochemical staining shows an increase of tyrosine hydroxylase (TH)
expression, AR, or IR, along with changes in co-expression of AR/TH and IR/TH. These
changes were blocked or reversed by prenatal treatments with flutamide or rosiglitazone,
or postnatal treatments with rosiglitazone or metformin, implicating AR and IR in
alterations of the VTA..
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INTRODUCTION

1.1

Sexual differentiation of the brain and prenatal programming of disease
In the 1990s, David Barker proposed that prenatal exposure to environmental

factors could increase susceptibility to disease and permanently program physiological
function in the adult. (1) While his studies focused on metabolic disease, it is now widely
accepted that among these factors are gonadal steroid hormones. Exposure of a female
fetus to these hormones during a critical time window of gestation permanently alters the
neuroendocrine axis, thus increasing the potential for disease (2). Specifically,
testosterone (T) and estradiol (E2) are critical in the prenatal programming of the
development of the brain, as well as growth, maintenance and function of certain
reproductive tissues. Masculinization and/or defeminization, both phenotypically and
behaviorally, is influenced by prenatal exposure to T (3) (4). Briefly, in the normal male
fetus, expression of the SRy gene on the Y chromosome results in the formation of testis
and the subsequent synthesis and release of testosterone (T). T influences the
organization of external and internal organs, resulting in the masculinized phenotype.
Thus, the female phenotype has been considered the “default” and does not require
organizational effects of steroids. In fact, estradiol levels of the mother do not influence
the fetus, due to a sequestering process. Throughout the body and brain, T can be
aromatized to E2 by the enzyme aromatase and act on estrogen receptors (ER) (5) (6). T
1

can also be converted to dihydrotestosterone and act on androgen receptors (AR) (7) (8).
T can influence the development of brain and brain function via actions on both
receptors, although the actions of E2 are most prominent. The organizational/activational
hypothesis, a model of steroid-induced sexual differentiation of the brain, states that
during the prenatal period, gonadal steroids permanently organize the brain, and
circulating hormones during adulthood could cause activation of this prenatal
programming (9) (10).
Exposure of a female fetus to excess androgens during the critical windows of
organization of body and brain causes phenotypical, reproductive and behavioral
abnormalities in humans. This has also been shown in other mammals, including
monkeys (11) (12), sheep (13,14) (15) (16), rats (17), mice (18), and guinea pigs (19).
Abnormal androgen exposure can occur when either the mother or the female fetus
produce excess androgens, including when the fetus is affected by congenital adrenal
hyperplasia (CAH) (20), or by exposure to exogenous factors, such as endocrine
disruptive agents (21) (22) or certain medicinal interventions (23). Also, female fetuses
from same sex twins can also be exposed to intrauterine androgens via the twin male
fetuses’ testosterone (24). The brain circuitry responsible for regulating metabolic and
reproductive function has been shown to be affected by prenatal exposure to excess
androgens. Thus, exposure of the female fetus to excess T does not simply result in
masculinization of the brain and body, but rather contribute to an abnormal state in the
female with increased vulnerability for disease. For example, exposure to excess prenatal
T leads to an increase in risk for obesity, insulin resistance, hyperlipidemia, infertility and
ovulatory dysfunction (25) (26). These reproductive and metabolic impairments are
2

commonly correlated with the most common female endocrine disorder, polycystic
ovarian syndrome (PCOS).
1.2

Polycystic ovarian syndrome
Polycystic ovarian syndrome is the most common reproductive syndrome,

affecting 10 percent of females of reproductive age (27). This syndrome is characterized
by luteinizing hormone (LH) hypersecretion, ovarian hyperandrogenism, and
hyperinsulinemia (26). While some evidence gives rise to the possibility of a genetic
etiology, the full presentation of the syndrome has not been explained by candidate genes
alone. Epigenetic factors, such as exposure to excess androgens during critical times of
development, are believed to contribute to the onset of PCOS (15) (26,28). Both fetal
and maternal hyperandrogenism can expose a fetus to excess androgens in utero.
Hyperandrogenic fetal ovary (29) and hyperandrogenic fetal adrenal cortex can cause
fetal hyperandrogenism either separately or together (20). Congenital adrenal hyperplasia
most commonly is a 21-hydroxylase enzyme deficiency in which the fetus produces
excessive concentrations of androgens (30) (31) (32). CAH women have polycystic
ovaries, elevated LH levels, hyperandrogenism, and infertility (20). With classical 21hydroxylase deficiency, females are exposed in utero to androgens due to excessive
adrenal androgen synthesis (30) (31) (32). When comparing women with classic CAH
and late-onset 21-hydroxylase deficiency, LH levels are only elevated with classic CAH
cases – those in which patients were exposed to androgens prenatally – along with an
increased LH response to Gonadotropin-releasing hormone (GnRH) agonist (30) .This
supports the idea that development of disorders such as PCOS and CAH could be caused
by exposure to either fetal adrenal or ovarian androgens during a critical time point in
3

development. Maternally, circulating levels of excess T during pregnancy exposes the
fetus, while maternal hyperinsulinemia induces excessive human chorionic gonadotropin
(HCG) secretion which leads to fetal ovarian hyperandrogenism (33). Such exposure to
excess testosterone can provide the permanent programming which leads to PCOS.
1.2.1

Symptoms and Diagnosis
Women with PCOS often first seek medicinal care due to irregular menstruation,

infertility, or clinical manifestations of hyperandrogenism. Amenorrhea, oligomenorrhea,
and prolonged erratic menstrual bleeding are commonly observed in PCOS women (34) only 30% of PCOS women will have normal menstrual cycles (35). Of PCOS women,
80% present with hyperandrogenism, and 70% present with hirsutism, a common clinical
presentation of hyperandrogenism (36). Also, infertility affects 40% of PCOS women,
along with spontaneos abortion reports ranging from 42-73% (37) (38).
Three groups offer diagnostic criteria: (1) the National Institutes of
Health/National Institute of Child Health and Human Disease (NIH/NICDH) (39), (2) the
European Society for Human Reproduction and Embryology/American Society for
Reproductive Medicine (ESHRE/ASRM, Rotterdam criteria) (40), and (3) the Androgen
Excess and PCOS Society (41). With all three groups, polycystic ovaries alone are not
considered sufficient for diagnosis and it has been increasingly clear that PCOS is
manifested by both reproductive and metabolic deficits. Table 1.1 summarizes each
individual criterion for clinical diagnosis.

4

Table 1.1

Criteria for the diagnosis of polycystic ovarian syndrome (modified from
Sirmans, et al 2014).

NIH/NICHD 1992

ESHRE/ASRM (Rotterdam
criteria) 2004
Exclusion of other androgen Exclusion of other androgen
excess or related disorders excess or related disorders
Includes both of the
following:
 Clinical and/or
biochemical
hyperandrogenism
 Menstrual
dysfunction

Androgen Excess Society
2006
Exclusion of other androgen
excess or related disorders

Includes two of the
Includes all of the following:
following:
 Clinical and/or
biochemical
 Clinical and/or
biochemical
hyperandrogenism
hyperandrogenism
 Ovarian dysfunction
 Anovulation or oligoand/or polycystic
ovulation
ovaries
 Polycystic ovaries

Abbreviations: NIH/NICH, National Institutes of Health/National Institute of Child Health and Human
Disease; ESHRE/ASRM, European Society for Human Reproduction and Embryology/American Society
for Reproductive Medicine.

1.2.2

Reproductive Deficits
The basic trait of PCOS is ovarian hyperandrogenism (42) (43). The Rotterdam

criteria define hyperandrogenism as highly variable between cases of PCOS, with
severity increasing with "classic" presentations (44). Due to this hyperandrogenism,
there is an increased recruitment of immature follicles from the primordial follicle pool
causing the presentation of polycystic ovaries (45) (46). Also, follicular growth is
impaired; 2-5 mm follicles positively correlate with increased serum T levels, and 6-9
mm follicles negatively correlate with fasting serum insulin and T levels, along with body
mass index (BMI). These finding indicate that follicles will not reach maturation due to
androgen excess and/or hyperinsulinemia (47).
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1.2.3

Metabolic Deficits
Before the manifestation of clinical features of PCOS, there is often a significant

weight gain in the patient (48). PCOS women often have increased abdominal adiposity,
which is responsible for insulin sensitivity (49). PCOS and obesity have both additive and
independent influence on insulin action (50). However, independent of obesity, 50%-70%
of PCOS patients are insulin resistant (51,52) (53) (54) (55). Due to the prevalence of
insulin insensitivity, metabolic syndrome is also very prevalent in women with PCOS
(56). Type 2 diabetes has a 7.5%-10% prevalence among PCOS women, while 30%-40%
of patients are glucose intolerant (57) (58). Dyslipidemia, including increased
triglycerides and low density lipoprotein-cholesterol (LDL) and decreased high density
lipoprotein-cholesterol (HDL), is an increased risk with PCOS (59). Also, due to
endothelial dysfunction and increased aldosterone concentrations, PCOS women are
more expected to have increases in blood pressure or hypertension compared to women
without the syndrome (60) (61) (62). Coronary artery calcium (CAC) scores and carotid
intima-media thickness (CIMT) in PCOS women have shown increased presentation of
sub-clinical atherosclerosis (63), and young PCOS women show greater CIMT compared
to BMI- and age-matched controls (64) (65,66) (67).

1.3
1.3.1

Behavioral deficits in polycystic ovarian syndrome
Mental Health Disorders
Recent studies support the claim that mood disorders, anxiety disorders and other

mental dysfunctions are increased in women with PCOS. Mood disorders – Major
Depressive Disorder (MDD), Dysthymic Disorder, and Depression Not Otherwise
6

Specified (DNOS) (68) - are the most prevalent in PCOS women. Studies report
significantly higher occurrence of depressive disorders in PCOS women (31%-35%)
compared to control women (10.7%-17.4%) after adjustments for BMI, family history of
depression, and history of infertility (69) (70). Hollinrake et al. also showed a significant
increase in anxiety disorders – General Anxiety Disorder (GAD), panic disorder, and
Obsessive Compulsive Disorder (OCD) (68) – of PCOS women (14%) when compared to
control women (1%) (69). Women with PCOS report greater body dissatisfaction than
women without the disease, even after controlling for BMI (71) (72). Interviews with
PCOS women document a negative perception of body image, including dissatisfaction
with appearance, perceived loss of femininity, feeling less sexually attractive, and selfconsciousness about appearance (73) (74). Debate continues on the etiology of the
increases in mental health dysfunction with PCOS, specifically with the role of
biochemical irregularities (75) (76). Several physical factors are speculated to play a role
in PCOS patients’ psychological well-being including: hirsutism, acne, menstrual
irregularity, infertility, weight difficulties (77), and long-term health risks (78). For
instance, Cipkala-Gaffin et al. showed the odds of, at a minimum, mild depression score
increased 6% for every unit increase in BMI (70).
1.3.2

Sexual Dysfunction
Women with PCOS often report a loss of satisfaction not only with their quality

of life, but also their sexual life and sexuality. PCOS women report significant
differences compared to control women in sexual areas including orgasm/completion
scores (79), vaginal lubrication, and initiating sex (80). PCOS patients also report they
feel that their partners are significantly less satisfied with their sex life, and that their
7

partners found them significantly less attractive (81). Women with PCOS find themselves
less sexually attractive, as well (81). An imbalance of sexual hormones, hirsutism, acne,
alopecia, fear of infertility, and obesity can contribute to a loss of sexuality and
contentment with sexual life (81). Obesity alone is a factor in sexual satisfaction (82)
(83) (84) suggesting that this trait could be an element of self-image in PCOS women. In
a study conducted by Morotti et al. showed lean women with PCOS, hyperandrogenism
and moderate hirsutism, did not differ from controls on body image or self-esteem (85).
However, Ferraresi et al. (2013) determined that regardless of obesity status, women with
PCOS had borderline or higher scores on the Female Sexual Function Index (FSFI) (86).
Infertility and involuntary childlessness, another trait of PCOS, has also been shown to
have a negative impact on sexual satisfaction (82), along with a feeling of loss femininity
(87).
1.4
1.4.1

Insulin sensitizers and anti-androgens in the management of PCOS symptoms
Insulin sensitizers
Insulin insensitivity, increased testosterone serum levels, and obesity are

important factors when considering women’s reproductive health. Treatments including
insulin sensitizers and androgen antagonists are assumed to lessen several undesirable
traits of PCOS. Hyperinsulinemia in PCOS women is often treated with insulin
sensitizers (88). Rosiglitazone increases a fat cell’s response to insulin by binding to the
peroxisome proliferator-activated receptors-γ (PPAR-γ) expressed in the cell (88).
Metformin, also used as an insulin sensitizer, works by inhibiting gluconeogenesis and
glycogenolysis which reduces hepatic glucose output (89) (90). Cataldo et al. (2005)
conducted a study in which 12-week treatments of rosiglitazone on PCOS patients
8

returned 55% of subjects to a regular ovulation (91), while Yilmaz et al. (2005) treated
subjects with rosiglitazone for 4 months, and restored 50% of obese patients and 60% of
lean patients menstrual cyclicity (92). Reduced risks of miscarriage, implantation failure
have been reported in PCOS women taking metformin trying to conceive, with
miscarriage rate positively affected by higher doses (93). However, none of the
previously discussed studies showed any effect on increased androgen sensitivity.
Weight loss is also an important therapeutic regimen when considering reproductive and
metabolic dysfunction in PCOS (94) (95). Lifestyle changes, including diet,
psychological support, and exercise, have been shown to reduce hyperandrogenism,
weight and waist circumference, hirsutism, and insulin resistance (96) (97).
1.4.2

Anti-Androgens
Anti-androgens, such as flutamide, have been used to treat hirsutism (98), acne,

and seborrhea (99) in PCOS patients. Flutamide, or 4’-Nitro-3’Trifluoromethylisobutyranilide, acts by competitively blocking nuclear binding sites of
androgens. The plasma metabolite, 2-hydroxyFlu is responsible for the anti-androgenic
mechanism (99) (100). Efficacies in androgen reduction and androgen metabolism
increase have also been shown (101,102) . Flutamide has been shown to induce a
significant decrease in serum levels of total and free testosterone, 5α-dihydrotestosterone,
dehydroepiandrosterone, and dehydroepoandrosterone sulfate (98) (103). Flutamide has
been shown to significantly decrease overall hirsutism scores, visceral and subcutaneous
fat, (104), and has been shown to decrease unwanted hair diameter most rapidly (98).
Paradisi et al. (99) (2011) showed that after 1.5 years of flutamide treatment, there was an
average of 90% improvement of acne and 87% improvement of seborrhea in PCOS
9

women. The study conducted by Gambineri et al. also suggested that treatment with both
flutamide and metformin (an insulin sensitizer) in PCOS women should be considered for
the most beneficial treatment (94).
1.5

Developing animal models of PCOS
In recent years, developments of animal models of PCOS have given insight into

the origins of the disease, as well as reproductive, metabolic and behavioral dysfunctions
(105). Studies in perinatal T-treated rodents, and prenatal T-treated sheep and nonhuman primates have been used to study the effects of in utero androgen exposure on the
development, pathology and mechanisms of PCOS(106)((107) (108) (109) . Studies in
animals (13) (26) (110) (111) and humans (20) have both shown prenatal exposure to T
adds to reproductive and metabolic dysfunction by affecting the hypothalamic-pituitarygonadal (HPG) axis. Female sheep (15) (111) (112), rhesus monkeys (113) (109) or rats
(114) (115)that are exposed to T during critical periods of development in utero, display
polycystic ovaries, disruptions in ovulatory cycles, abnormal gonadotropin secretion and
elevated levels of LH.
1.6

Prenatal testosterone treated sheep model
Our research group has developed a prenatal T-treated sheep model of PCOS to

study the effects of prenatal exposure to androgens on the brain, peripheral tissues and
social behavior, which has been extensively studied and documented (26). Sheep have
been used at length to provide models for study of fetal programming and development of
adult disease (116). The sheep is an ideal model for studies of programming beginning in
utero and following through until adulthood, as their gestation period is 147 days, and
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female puberty onset begins at 28 weeks of age. Since sheep are precocial, fetal
development is on a similar timeline to that of humans (105). Reproductive cyclicity
mediators are comparable to those neuroendocrine functions of humans (117) (118).
Unlike rodents, full follicular differentiation is complete before birth in sheep, like
humans and other non-human primates (105). Sheep are domesticated animals, and
therefore, are able to be kept in a natural flock setting, decreasing the stress of caging, as
well as allowing the study of behavioral interactions (119). Due to their size, the sheep is
more versatile for study compared to the rodent. For instance, sheep size permits
multiple neurotransmitter measures, non-invasive sequential monitoring of ovarian
follicular dynamics, and detailed and repetitive hormonal profiling, all with minimal
stress to the animal. Finally, sheep are cost effective when compared to non-human
primates (105).
1.6.1

T30-90 (T60) Model
The sheep model used by our laboratory consists of female sheep treated

prenatally with testosterone from gestational days 30-90 (T60) of the 147 day gestation.
This time frame was chosen as the male sheep fetus begins to produce testosterone by
gestational day 30 (120), which marks the beginning of the sexual differentiation of the
hypothalamic-pituitary-gonadal axis lasting until day 90 of gestation (121) (122) (123)
(124). The dosages of T used in our model results in levels to which the female fetus is
exposed that are comparable to the natural or physiological levels of the male fetus. The
prenatal-T exposed females are born with completely virilized genitalia, with an empty
scrotal sack in place of a vaginal opening and a functioning pseudopenis used for
urination (122) (125). These females also have impaired reproductive and
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neuroendocrine dysfunction including sporadic ovulation, blunted LH surge, LH
hypersecretion and multi-follicular ovaries (122). Cyclicity in these females begins at
puberty and gradually decreases over the next two years (13-15 Jackson) (13) (15) (112).
Finally, prenatal T-treated ewes are hyperinsulinemic, with decreased insulin sensitivity
measureable at 5 weeks of age (126) (107). Figure 1.1 diagrams the design of this animal
model, while Table 1.2 shows the shared symptoms between this model and PCOS
women.

Figure 1.1

Schematic diagram illustrating the prenatal testosterone (T) sheep model

The pregnant mother is injected with T twice weekly from gestational days 30-90. Two
years after birth, the adult prenatal T treated female offspring is ovariectomized (OVX),
receives an estradiol implant (designed to mimic follicular phase levels of E2), sacrificed,
and the brain is collected for research. (Cernea et al. 2014, unpublished)
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Table 1.2

Summary of symptoms shared between prenatal T-treated ewes and women
with PCOS. (modified from Dumesic, et al. 2007)

Prenatal Ttreated Ewes
Anovulation

Hyperandrogenism

Reduced hypothalamic sensitivity to steroid negative 
feedback
Polycystic ovaries

Impaired fertility

Fetal growth retardation

Hypertension

Increased risk of obesity

Insulin Resistance

Hyperlipidemia

Altered Sexual Function

Attributes

1.6.2

Women with
PCOS












Alterations in behavior
Prenatal T-treated sheep have altered goal-directed behavior. They are high

ranking in the flock and comparable to rams and display masculine sexual behavior. In
2008 Roberts et al. showed that prenatal-T exposed females showed severely reduced
lack of female-typical mating behavior, but directed male-typical mating behavior
towards control females. (125) (127). More recent, unpublished studies from our
laboratory have shown that prenatal T also affected the female’s motivation to engage in
sexual behavior with males; evidenced by significantly less appetitive behaviors towards
the sexual partners, indicating that the prenatal T-treated females do not initiate sexual
behavior. Moreover, our laboratory has unpublished data showing that prenatal T-treated
females show increased food reward behavior. Thus, prenatal T treatment altered goaldirected behaviors related to sexual behavior and food intake.
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1.7

The mesolimbic dopamine system
The mesolimbic dopamine system is a key neural substrate for reward behavior.

This neural circuitry regulates natural reward behaviors, including food intake (128),
reproductive behavior (129), and maternal behavior (130). The mesolimbic system is
comprised of dopamine neurons in the ventral tegmental area (VTA) that project to the
hypothalamus, amygdala, and ventral striatum, including the nucleus accumbens (NAc)
(129).
1.7.1

Sex behavior and food reward
Increased levels of extracellular dopamine in the striatum and NAc of female rats

during mating, supports the idea of mesolimbic involvement in female reproductive
behavior motivation and reward (131) (132). Female rats who are able to initiate and
control the rate of copulation, or pacing, have a higher dopamine release than females
who do not initiate or pace, suggesting that dopamine may be involved in goal directed
behaviors and the motivation to initiate sexual behavior (133,134). Female rats also
develop a condition placed preference (CPP) for sex reward-associated environments
(134-136).
The VTA is responsible for food reward, including stress- and cue-induced
feeding, and motivation for palatable food (137). Dopamine signaling is most involved
in the achievement of sought food, as well as determining new food rewards and their
predictive cues (138-142). Glutamatergic inputs combined with environment stimuli to
form cues increase the dopamine signaling in the VTA, then trigger reward seeking,
whether it be for food, sex or drugs (137,139,143,144). Thus, the VTA dopamine
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neurons are a key substrate for motivation and reward seeking behaviors, especially
related to food and sexual behavior.
1.8

Dopamine signaling in the midbrain
The majority of dopamine neurons in the midbrain comprise two functionally

different but neighboring groups, the A10, or the VTA, and the A9. The A10 group, or
the VTA is discussed above. The A9 group, or Substantia Nigra (SN), consists of the
lateral midbrain dopamine neurons that project to the dorsal striatum, or the meso-striatal
pathway (145). SN dopamine neurons are vital to control and voluntary movement (145)
(146).
1.8.1

Sex differences in VTA dopamine system
Dopamine neurons in the rat VTA and SN express intracellular hormone

receptors, suggesting that these neurons may be responsive to gonadal hormones (147)
(148) (149). Kritzer et al. (1997) determined that in the rat, AR-immunoreactive (AR-ir)
cells outnumbered ER- immunoreactive (ER-ir) cells in the VTA, and in some areas,
including the SN, ER-IR cells were non-existent (147). Using tyrosine hydroxylase
(TH), a rate-limiting enzyme catalyst of the precursor of dopamine, the colocalization of
AR-ir/TH and ER-ir/TH was determined, revealing no ER-ir/TH overlap, but an almost
100% colocalization of AR-ir/TH cells (147). Johnson et al. (2010) showed castration of
adult rats and mice led to an increase in TH-ir VTA cells, with testosterone replacement
returning TH-ir cell numbers to that of controls (150). In females, TH-ir cell numbers
were significantly reduced in ovariectomized animals compared to intact or hormonereplaced females (151). Also, prenatal and perinatal exposure of glucocorticoids and
15

other steroid hormones have been shown to influence dopamine neuron counts (146).
Such evidence for the roles of hormones on midbrain dopamine neurons, gives reason to
believe steroid exposure, either prenatally or postnatally, can alter the midbrain dopamine
system.
1.8.2

Dopamine and Insulin Receptor
As discussed above, dopamine neurons in the VTA are suggested for roles in

motivation and reinforcing of food intake, along with incentive and anticipatory activity
or preference for palatable food (152). In 1997 it was shown that insulin receptors (IR)
are found throughout all brain regions, with the highest densities found in the
hypothalamus and cerebellum (153). In 2003, Figlewicz documented the co-expression
of IR in TH-ir cells throughout the VTA and SN, as well as IR-positive cells that were
TH-immunonegative (TH-IN), supporting the idea of the midbrain dopamine system
being a target for metabolic hormones (154).Insulin, either directly injected into the VTA
or administered intracerebroventricularly (i.c.v.) reduces motivation to ingest sucrose
(155), CPP for high fat food (156) , and inhibits opioid-induced feeding (157) and
palatable food ingestion (158). Also, sucrose ingestion, prompted by stimulation of muopioid receptors in the VTA was blocked by co-administration of insulin (158), and
Bruijnzeel et al. (2011) showed decreases in brain rewards followed an increase in insulin
levels (159). Insulin resistance is also implicated in the disruption of the VTA pathways
possibly leading to increased caloric intake, and in turn, obesity (152). In summary,
ample evidence exists linking insulin involvement with the VTA, with the hypothesis that
insulin receptor insensitivity may increase food reward behaviors.
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1.9

Working Hypothesis
Female sheep exposed to excess T during days 30-90 of gestation display an array

of symptoms similar to those reported in women with PCOS. Specifically, prenatal Texposed ewes display masculinized food-reward seeking behavior, as well as
masculinized sexual behavior. As the VTA is a key neural substrate for regulation of
reward behaviors, including sex and food seeking, we hypothesize that prenatal T alters
dopamine signaling in the VTA, specifically via action on androgen and/or insulin
receptors.
1.9.1

Previous findings from the Coolen laboratory
Indeed, in previous studies, it was shown that prenatal T treatment either for 30 or

60 days during gestation (from gestational days 60-90 or 30-90) significantly increased
TH expression in the adult female offspring. Moreover, sex differences were detected,
with males have more neurons that expressed TH compared to females, and prenatal Ttreated females being identical to males. It was also shown that the effects of prenatal T
were mimicked by prenatal exposure to DHT, suggesting that prenatal T affects VTA
dopamine via action on androgen receptors. Finally, it was found that prenatal T
significantly increased number of AR-containing cells in the VTA, suggesting that
prenatal T caused hyper responsiveness to androgens in VTA neurons. Together, these
findings implicate androgenic action of T in the alteration of the mesolimbic dopamine
system. See Figure 1.2 and Figure 1.3.
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Figure 1.2

Distribution of TH-ir neurons in the sheep midbrain

Representative images and contour map drawings of the male rostral (A,B), middle (E,F),
and caudal (I,J) levels and female rostral (C,D), middle (G,H) and caudal (K,L) levels of
the VTA and SN. Red boxes represent the area used for analysis of VTA (700 X
800µm). Black boxes represent the area of the SN (700 X 800m) used for analysis.
Contour drawings illustrate the location of central aquaduct (AQ), dorsal tegmental
bundle (DTB), fasiculus retroflexus (FR), cerebral peduncle (CP), posterior commissure
(PC), red nucleus (RD), central grey (CG), oculomotor nerve bundles (OM), oculomotor
nucleus (ON). Scale bar 2mm. (From Brown E and Coolen LM; M.Sc. Thesis 2010,
unpublished).
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Figure 1.3

Graph of TH-ir neurons in the sheep midbrain

Mean number (± SEM) of TH-ir cells in the VTA (A) and SN (B) in control male (n=4),
control female (C60; n=8) prenatal T-treated (T60; n=8), T co-treated with flutamide
(T60+F; n=4), dihydrotestosterone-treated (DHT; n=6) and estradiol-treated (E; n=8)
females. * indicates statistically significant difference compared to male controls
(p<0.05). # indicates statistically significant difference compared to C60 females.
(p<0.05) (From Brown E and Coolen LM; M.Sc. Thesis 2010, unpublished).
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1.9.2

My Research Goals
Study 1: Previous studies showed sex differences of the neurons of the VTA;

however, it was undetermined whether this was due to an increase in the size or volume
of the VTA and/or increased presence of neurons in males and prenatal T-treated female
sheep compared to control female sheep. Therefore, the first aim of this thesis was to
determine if the sex differences and/or prenatal T only affects TH cells, or if differences
exist in non-TH-ir neurons in the VTA, as well. Also, the volume of brain regions has
been reported to be influenced by sex differences or effects of steroids, for example in the
hypothalamus or bird song system (160) (161) (162). Therefore, a second goal of the first
study was to determine whether the volume of the VTA was affected by prenatal T or sex
differences in sheep. Immunohistochemistry for TH and histological visualization of nissl
to visualize all cells was used along with stereological analysis to quantify the total
numbers of TH-ir, non-TH-ir neurons, and the volume of the entire VTA in control
males, and control and prenatal T-treated females.
Study 2: The second objective of this thesis was to investigate the hypothesis that
prenatal T influences VTA TH neurons by acting on AR, based on evidence that AR
action is involved in the organizational effects of testosterone on dopamine neuron
expression in male rodents (147-149) and sheep (Brown et al. 2014, submitted). To test
this hypothesis we determined if the alteration of the VTA by prenatal T can be
attenuated by co-treatment with an androgen antagonist. This was first tested by
observing TH-ir expression in adult ewes treated with either prenatal T alone, or prenatal
T with the androgen antagonist flutamide. Next, we tested the hypothesis that prenatal T
treatment caused functional hyperandrogenism, i.e. increased expression of AR, by
20

assessing AR immunoreactivity in control females versus females treated with prenatal T,
and prenatal T with flutamide using immunohistochemistry. Finally, we examined if the
increased expression of AR in prenatal T-treated ewes was specifically increased in VTA
dopamine neurons using dual fluorescent stained sections of control, and prenatal T
females.
Study 3: The third, and final aim of this study was to determine the influences of
prenatal T on VTA TH neurons via actions of insulin receptors (IR), based on previous
findings that IR expression in the VTA may be implicated in mediating the effects of
hormones on the mesolimbic dopamine system and reward seeking behavior (152)
(154,159). To determine if the effects of prenatal T could be prevented or reversed with
insulin sensitizers, control ewes (C) or prenatal T-treated (T) ewes with additional groups
having been treated with either prenatal rosiglitazone (R), postnatal rosiglitazone (+R) or
postnatal metformin (+M), were evaluated using immunohistochemistry. Next, the
expression of IR in VTA TH neurons was tested with dual immunofluorescence. Once IR
was shown to be co-expressed with TH, the effects of prenatal T, along with prenatal and
postnatal treatment with rosiglitazone were studied. Finally, the last hypothesis to be
studied in relation to the final aim was to determine possible interactions between IR and
AR by analyzing AR expression in ewes treated with the previously discussed treatments
compared to controls.
Together, these studies may shed light on the underlying mechanisms of the fetal
origin of PCOS. The sheep utilized in these studies were raised on a specialized research
facility (research farm) at the University of Michigan, in Ann Arbor, MI. The tissues used
for my three studies were collected prior to my arrival in the laboratory and I was
21

therefore not involved in the daily experimental treatments of these animals. However, I
have conducted research at the research farm during two occasions and been involved
with two studies involving similar groups as described in this thesis. Specifically, I
conducted steroid manipulations in two experiments consisting of prenatal T-treated ewes
and ewes treated prenatally or postnatally with insulin sensitizers or flutamide. I also
performed tissue and brain collections as described in this thesis, in those same two
experiments of animals that will be used for future studies. Those future studies will test
hypotheses that are partially based on the findings presented in this thesis.
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CHAPTER II
METHODS AND MATERIALS

2.1

Animals and General Care
Female Suffolk ewes were purchased in the local Michigan area and cared for at

the University of Michigan Sheep Research Facility (Ann Arbor, MI). Breeding, housing,
nutrition, lambing, and prenatal treatment details have been previously described (16)
(112) (163). Briefly, ewes were group fed a diet of corn and alfalfa hay prior to breeding
daily to attempt an increase in energy and ovulation rate. Post breeding, ewes were group
fed daily then put to pasture under a natural photoperiod. After birth, mother and lamb
were housed individually for 3 days, and then moved to a barn for group housing. Lambs
were weaned at 8 weeks of age. After weaning, lambs were given free access to water
with a daily maintenance feeding outdoors at a natural photoperiod. All experimental
procedures were approved by the University Animal Care and Use Committee at the
University of Michigan and were in accordance with the National Research Council's
Guide for the Care and Use of Laboratory Animals.
2.2
2.2.1

Experimental Groups
Study 1: Prenatal T treatment
For generation of prenatal T-treated females (n=6), pregnant Suffolk ewes of

known conception dates received twice weekly 2 ml intramuscular injections of 100 mg
39

testosterone propionate (~1.2 mg/kg; Sigma-Aldrich Corp., St. Louis, MO, USA) in
cottonseed oil for 60 days, between gestational days 30 to 90 of the 147 day gestational
term. The dose and mode of T propionate treatment has been shown to achieve a
concentration of T comparable to adult males in pregnant ewes and levels of T in female
fetuses that are comparable with that of male fetuses (~0.6 ng/mL in the umbilical arterial
blood) (164,165). The pregnant ewes for the control female offspring (n=5) did not
receive vehicle since no differences in reproductive attributes were found between
vehicle-treated and non-vehicle controls in a previous study (112). At two years of age,
all prenatal T-treated and control females were ovariectomized 2 months before brain
collections, and treated with progesterone implants (CIDR; Inter AG, Hamilton, Waikato,
New Zealand) and estradiol (Silastic implants) to mimic late follicular phase levels as
previously described. Control males (n=3) were bred and raised on the farm under
similar conditions to the ewes, did not receive any prenatal treatments, and were
gonadally intact at the time of brain collections.
2.2.2

Study 2: Prenatal intervention with androgen receptor antagonist
Prenatal T-treated (T; n=5) and control females (C; n=7) were generated as

described above. In addition, prenatal T-treated and control females co-treated with
flutamide (TF; n=11; and CF; n=7) were generated in the same manner, but with
additional daily subcutaneous injections of flutamide (F; 15 mg/kg; Sigma-Aldrich)
dissolved in dimethylsulfoxide (400 mg/ml; Sigma-Aldrich) (127). The dose and route of
administration of flutamide were selected based on a study of prenatal treatments in
rhesus macaques (166). At two years of age, all ewes were ovariectomized 2 months
before brain collections, and treated with progesterone and estradiol implants (CIDR;
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Inter AG, Hamilton, Waikato, New Zealand) to mimic late follicular phase levels as in
study 1.
2.2.3

Study 3: Prenatal and postnatal interventions with insulin sensitizers
Prenatal T-treated (T; n=5) and control (C; n=7) ewes were generated as

described in study 1. In addition, prenatal T-treated and control females co-treated
prenatally with rosiglitazone (TR; n=7; and CR; n=6) were generated in the same
manner, but with additional daily oral treatment of rosiglitazone (Avandia;
GlaxoSmithKline; Durham, NC) at a dose of 8 mg/ewe. This dose of insulin sensitizer
administered postpubertally improved reproductive function in prenatal T-treated females
(167). In addition, groups of control and prenatal T-treated ewes received postnatal
treatments with insulin sensitizers, rosiglitazone (T+R; n=8; and C+R; n=6) or metformin
hydrochloride (TEVA Pharmaceutical IND. LTD, Jerusalem, Israel; T+M; n=4; and
C+M; n=5) beginning at 8 weeks of age. Treatment consisted of daily oral administration
of 0.11 mg/kg Rosiglitazone or 7.1 mg/kg metformin. These dosages are comparable to
those given to women with PCOS (168,169).
2.3

Tissue Collection
Prior to sacrifice animals were given two intravenous injections of herapin

(25,000 U at 10 min intervals; Abraxiz Pharmaceutical Products, Schumberry, IL). Ewes
were then deeply anesthetized with an intravenous administration of sodium pentobarbital
(390 mg/ml/kg; Fatal Plus, Vortech, Dearborn, MI) and rapidly decapitated. Heads were
perfused via internal carotid arteries with 6L of 4% paraformaldehyde (Sigma-Alrich)
dissolved in 0.1M phosphate buffer (PB; Sigma-Aldrich) containing 0.1% sodium nitrate
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(Sigma-Alrich). Post perfusion, brains were placed in the same fixative for 18 hr at 4⁰C.
Blocks of tissue containing the midbrain were dissected and placed into 30% sucrose in
PB at 4⁰C. Coronal sections were then cut into 10 parallel series at 45 µm using a
freezing sliding microtome (Microm HM400R, Walldorf, Germany). Until further use,
sectioned tissues were stored in cryoprotectant (30% ethylene glycol, 0.1% sodium azide,
30% sucrose in 0.1M PB) at -20⁰C.
2.4

Immunohistochemistry: General Methods
All incubations were performed at room temperature with gentle agitation. Free-

floating sections were washed thoroughly between each step with 0.1M phosphatebuffered saline (PBS; pH 7.35) unless otherwise specified. Antibody incubation solution
consisted of 0.1M PBS with 0.4% Triton X-100 (Sigma-Aldrich) and 4% normal goat
serum (Jackson ImmunoResearch Laboratories, West Grove, PA). Sections were blocked
with 1% (unless otherwise specified) hydrogen peroxide (10 min, H2O2; Fisher
Scientific, Pittsburgh, PA) to eliminate the endogenous peroxidase activity and
incubation solution prior to incubation with primary antibody to prevent non-specific
background labeling.
Immunohistochemistry controls for antibodies included removal of all signal by
preabsoprtion of the primary antibodies with the corresponding peptide antigen (Santa
Cruz; AR: J1012 and IRβ: E1413) at a concentration of 10-25 µg/ml for 24 hrs at 4⁰C.
See Figure 2.1. All antibodies resulted in patterns of labeling previously reported in other
species (147,170,171).

42

Figure 2.1

Preabsorption controls for AR and IRβ antibody.

Antibody for AR was preabsorbed with the synthesizing peptide, resulting in a lack of
staining (B), compared to the AR-ir resulting the non-absorbed antibody (A). Similarly,
antibody for IRβ was preabsorbed with the synthesizing peptide, resulting in a lack of
staining (D), compared to the IRβ-ir resulting the non-absorbed antibody (C), and thus a
lack of dual labeling in the dual immunofluorescent protocol for IRβ and TH (E, F, G, H).
Scale bar indicates 50 µm.
2.4.1

Immunoperoxidase techniques: Tyrosine Hydroxylase or Androgen
Receptor
Tissue sections were incubated overnight (17 hr) with mouse monoclonal

antibody specifically recognizing tyrosine hydroxylase (TH; Millipore) at a 1:40,000
(Study 1 and 2) or 1:15,000 (Study 3) dilution in blocking solution, or 1:300 dilution
(Study 2 and 3) of polyclonal antibody specifically raised against androgen receptor (AR;
Santa Cruz , sc-816, lot #H1913). Next, sections were incubated with biotinylated goat
anti-mouse IgG (Vector Laboratories, Burlingame, CA; 1:500 in incubation solution for 1
hr) and by avidin-horseradish peroxidase complex (ABC-elite; Vector Laboratories;
1:500 in PBS for 1hr). TH-immunoreactivity was visualized using diaminobenzidine
(DAB; Sigma-Aldrich, St. Louis, MO) in PB containing 0.0125% hydrogen peroxide,
resulting in a reddish-brown reaction product. After washing, the sections were then
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mounted on glass slides using 0.3% gelatin in ddH2O, air dried and coverslipped with
DPX (Electron Microscopy Sciences, Fort Washington, PA), or counterstained with
cresyl violet (Study 1) and coverslipped.
2.4.2

Immunohistochemistry: dual-label immunofluorescence for Insulin
Receptor or Androgen Receptor and Tyrosine Hydroxylase
Tissue sections were incubated with rabbit polyclonal antibody against the beta

sub-unit of the insulin receptor (IRβ; 1:400 dilution; Santa Cruz, sc-711, lot #D1113) or
polyclonal antibody specifically raised against androgen receptor (AR; 1:600 dilution;
Santa Cruz , sc-816, lot #H1913) overnight (17 hr). Sections were then incubated with
biotinylated goat anti-rabbit IgG (GARb; 1:500 dilution, 1 hr, Vector Laboratories,
Burlingame, CA, USA), ABC-elite (1:500 dilution in PBS, 1 hr, Vector Laboratories),
biotinylated tyramide (Tissue Sample Amplification (TSA); 1:250 dilution in PBS with 1
µl of 3% H2O2, 10 min, Perkin Elmer Life Sciences, Waltham, MA, USA), and Alexa
555 conjugated streptavidin (1:100 dilution in PBS, 30 min, Millipore). Next, sections
were incubated with mouse monoclonal antibody against tyrosine hydroxylase (TH;
1:500 dilution, 17 hr, Millipore) and with goat anti-mouse Alexa 488 (1:100 dilution in
PBS, 1 hr, Millipore). Sections were then mounted onto Superfrost/Plus Microscope
Slides (Fisher) and cover slipped with gelvatol (172).
2.5
2.5.1

Cell counts and data analysis
Unbiased Stereology (Study 1)
Using StereoInvestigator software (MicroBrightField, Williston, VT, USA) and

the optical fractionator method, unbiased stereological estimations of the total number of
TH-ir and non-TH-ir/nissl stained cell bodies in the VTA as well as total volume of the
44

VTA in sections from males (n=3), control females (n=5), and prenatal T-treated females
(n=6) were obtained. Sections stained for TH with DAB and counterstained with chresyl
violet were imaged using a Leica microscope (DM5000B, Leica Microsystems; Wetzlar,
Germany) attached to a CCD camera (Microfire, Optronics, Goleta, CA, USA) and a
motorized stage controlled by StereoInvestigator software. The cerebral peduncle and the
diameter of the cerebral aqueduct were used as landmarks to determine the most rostral
end of the VTA and thus the location to initiate the stereological analysis. The seven
subsequent sections were chosen for analysis in a rostral-caudal manner, for a total of
eight tissue sections per animal. Prior to immunoprocessing, the sections were 45 µm
thick and every tenth parallel section was included in the analysis. Section thickness was
determined by recording the distance between the planes at which the first object within
the area of analysis to come into focus, and the plane at which the last object went out of
focus. The average final section thickness was 28.2 µm, accounting for shrinkage. The
region of interest (i.e. the VTA) was delineated at 5x magnification. A grid measuring
700 x 350 µm was then positioned over this contour tracing; the individual counting
frame used measured 190 x 190 µm with a dissector height of 10 µm. Individual cell
bodies were identified by an observer blinded to treatment groups at 40x magnification,
based on the identification of the nucleus of each neuron. Cells stained for TH with a
visible nucleus were marked TH-ir, while cells stained with cresyl violet but not TH were
marked as non-TH-ir. The optical fractionator method was used to estimate the total
numbers of neurons. VTA regional volume was determined using planimetry. The
coefficient of error for all samples was ≤0.13.
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2.5.2

TH: DAB (Study 2 and 3)
In studies 2 and 3, quantitative analysis was conducted using a standard area of

analysis to count numbers of TH-ir cells. Two sections from the VTA were analyzed for
each animal. Groups included: C (n=7), CF (n=7), T (n=5) and TF (n=11) (Study 2) and
C (n=6), CR (n=5), C+R (n=6), C+M (n=5), T (n=5), TR (n=7), T+R (n=6) and T+M
(n=4). Landmarks including the ocolomotor nerve fibers were used to identify the
identical rostrocaudal level for analysis in each animal. Images of immunostained
sections were captured using x10 objective and Leica microscope (DM5000B, Leica
Microsystems; Wetzlar, Germany) attached to a CCD camera (Microfire, Optronics,
Goleta, CA, USA) with Microbrightfield Software (Microbrightfield, Inc). Cell counts
were performed in a standard area of analysis (2000 X 1600 µm for VTA (Studies 2 and
3) and Substantia Nigra (SN; Study 1) as described in our previous study (Brown et al.
2014, submitted) by an observer blinded to the experimental group, and the mean number
of TH-ir cells per hemisphere, was calculated based on the two counts for each animal.
The means were calculated for each group and expressed as mean +/- SEM.
2.5.3

AR (Study 2) or IR (Study 3) coexpression with TH Cell Counts
Fluorescent sections of the VTA were captured at original magnifications of x20

using a Leica microscope (DM5000B, Leica Microsystems; Wetzlar, Germany) attached
to a CCD camera (Microfire, Optronics, Goleta, CA, USA). The same landmarks as
described above were used to select the identical rostrocaudal level for each analysis.
Standard areas (2000 X 1600 µm) were used and the number of single-labeled TH-ir and
AR-ir neurons, and double-labeled AR/TH neurons (Study 2) or single-labeled TH-ir and
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IR-positive neurons, and double-labeled IR/TH neurons were counted using Neurolucida
software (MBF Bioscience, Williston, VT) by an observed blinded to treatments.
2.6

Statistical Analyses
The statistical software SigmaPlot 11.0 for Windows (DUNDAS Software Ltd.,

Germany) was used for all statistical analysis, with confidence levels of 95%.
In Study 1, numbers of TH-ir, non-TH-ir, or volume were compared using One
Way ANOVA and Holm-Sidak’s method for all pairwise multiple comparisons.
In Study 2, Two Way ANOVA analyses were used to determine effects of
prenatal T or flutamide treatments on numbers of TH-ir cells, AR-ir cells, co-expression
of AR-ir in TH-ir cells, or co-expression of TH-ir in AR-ir cells; with Holm-Sidak’s
method for all pairwise multiple comparisons.
In Study 3, statistical analyses were performed separately to compare the control
(C) and prenatal T-treated (T) females with the groups treated either prenatally with
rosiglitazone (R), postnatally with rosiglitazone (+R), or postnatally with metformin
(+M). Two Way ANOVA analyses were used to determine effects of prenatal T
treatment, and the effects of either prenatal rosiglitazone, postnatal rosiglitazone, or
metformin treatment on numbers of TH-ir cells, IR-ir cells, or co-expression of IR-ir in
TH-ir cells; with Holm-Sidak’s method for all pairwise multiple comparisons.
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CHAPTER III
RESULTS

3.1

Study 1: Stereological analysis of effects of prenatal T on TH and non-TH
neurons in VTA
Previous studies in our laboratory have shown that males have more neurons that

express TH in the VTA compared to females. Moreover, prenatal exposure to T increased
the numbers of TH-ir neurons in adult females. But several questions remained
outstanding and were addressed in this first study: 1. Were the sex differences and/or the
effect of prenatal T specific for TH, or were differences also present in non-TH-ir
neurons in the VTA?; and 2. Was the volume of the VTA affected by prenatal T or by sex
differences?. These questions were addressed using an unbiased method for cell counting,
i.e. stereological analysis.
Statistical analysis confirmed an overall difference between groups (F (2,11)=
26.78; p<0.001). Specifically, control males had higher number of TH-ir neurons than
control females (p<0.001). Moreover, prenatal T-treated females had significantly more
TH-ir cells in VTA compared to control females (p<0.001) and were identical to control
males. In contrast, there were no sex differences or effects of prenatal T in the numbers of
non-TH-ir neurons in the VTA and in the total volume of the VTA. Hence, effects of
prenatal T were specific to TH-ir neurons in the VTA. See Figure 3.1.
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Figure 3.1

Stereological analysis of effects of prenatal T treatment.

Representative image of VTA sections immunostained for TH (brown) and counter
stained using chresyl violet (purple) control female. Example non-TH-ir neurons are
identified with arrows (A). Scale bar indicates 50 µm. Graphs show numbers of TH-ir
cells (B), non-TH-ir cells (C) and total VTA volume (in cubic millimeters; D) in control
females (C Female), prenatal T-treated females (T Female) and control males (C
Male). Data are presented as mean ± SEM. * indicates statistically significant difference
from female control. # indicates statistically significant difference from male control.

3.2
3.2.1

Study 2: Prenatal T influences VTA TH neurons via androgen receptors
Prenatal T treatment affects TH expression via action on androgen
receptors
To test the hypothesis that prenatal T caused an increase in numbers of TH-ir

neurons in the VTA via activation of androgen receptors (AR), TH-ir expression was
analyzed in adult females treated prenatally with either T or with T and flutamide. Two
Way ANOVA analysis showed effects of prenatal T (F(1,26)=70.24; p<0.001), flutamide
(F(1,26)=32.68; p<0.001), and an interaction (F(1,26)=57.47; p<0.001). Post hoc
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analyses showed that prenatal T treated females had significantly more TH-ir neurons in
the VTA compared to control females (p<0.001), again confirming our previous findings.
Moreover, prenatal co-treatment with flutamide was able to block this effect of prenatal
T, such that numbers of TH-ir cells in prenatal T and flutamide co-treated females (TF)
did not differ from control females (C or CF), and were significant lower than prenatal T
females (T; p<0.001) (Fig. 3.2). Prenatal flutamide treatment alone (CF) had no effects
on TH-ir neurons in the VTA. These findings indicate that prenatal T influenced TH
expression in the VTA via action on AR.
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Figure 3.2

Prenatal flutamide prevents effects of prenatal T on VTA TH expression.

Representative images of VTA sections immunostained for TH in control females (A; C),
and females treated prenatally with testosterone (B; T), flutamide (C; CF), or prenatal
testosterone and flutamide (D; TF). Scale bar indicates 100 µm.
Graph shows numbers of TH-ir cells in the VTA of the four groups (E). Data are
presented as mean ± SEM and * indicates statistically significant difference from control.

3.2.2

Prenatal T treatment increases AR expression in VTA
Next, we tested the hypothesis that prenatal T increased AR expression in VTA

TH-ir neurons. Two Way ANOVA analysis showed effects of prenatal T (F(1,25)=41.13;
p<0.001), flutamide (F(1,25)=26.66; p<0.001), and an interaction between prenatal T and
flutamide treatments (F(1,25)=58.94; p<0.001) (Fig. 3.3). Post hoc analyses showed that
prenatal T treated females had significantly more neurons containing AR-ir in the VTA
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compared to control females (p<0.001) in the VTA. Moreover, prenatal co-treatment
with flutamide blocked the effect of prenatal T (TF), such that numbers of AR-ir neurons
were lower compared to prenatal T-treated females (T; p<0.001) and did not differ from
those in control females (C and CF). Finally, prenatal treatment of flutamide alone (CF)
did not affect AR expression.

Figure 3.3

Prenatal flutamide prevents effects of prenatal T on VTA TH expression.

Representative images of VTA sections immunostained for AR in control (A) and
prenatal T-treated female (C). Areas indicated by the squares in A and B are shown
enlarged in B and D resp. Scale bar indicates 100 µm. Graph (E) shows numbers of AR-ir
cells in the VTA of the four groups: control females (C) and females treated prenatally
with testosterone (T), flutamide (CF), or prenatal testosterone and flutamide (TF). Data
are presented as mean ± SEM and * indicates statistically significant difference from
control.
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3.2.3

Prenatal T treatment increases AR expression in TH-ir neurons in VTA
Next, we tested that prenatal T increased AR specifically in VTA TH neurons

using dual fluorescent stained sections of control and prenatal T-treated animals. First, we
determined that AR is indeed expressed in TH-ir neurons in the VTA: In control females,
54% of AR expression was found in TH cells, while 56% of VTA TH-ir cells express
AR. Next, analysis of the dual fluorescently stained sections confirmed that prenatal T
increased numbers of AR-ir neurons in the VTA of adult females (p<0.001; Figure 3.4).
Moreover, prenatal T increased AR particularly in TH-ir neurons as both the percentages
of TH cells expressing AR, and the percentages of AR found in TH cells were
significantly increased compared to control females (p<0.001; Figure 3.4).
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Figure 3.4

Prenatal T affects AR expression in VTA TH cells.

Representative images of a VTA section in a prenatal T-treated female stained with
immunofluorescence for TH (green; A) and AR (red; B). Right panel (C) is a merged
image. Arrows indicate some examples of TH-ir neurons in the VTA that co-express AR
(arrows). One example of AR expression in a non-TH-ir neuron (arrowhead) and a TH-ir
neuron without AR expression (small arrow) is also indicated in the image. Scale bar
indicates 50 µm. Graphs show numbers of AR-ir cells (D), TH-ir cells (E), percentages of
AR cells that co-express TH (F), and percentages of TH-ir cells that co-express AR (G) in
the VTA. Data are presented as mean ± SEM and * indicates statistically significant
difference from control.
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3.3

Study 3: Prenatal T influences VTA TH via insulin receptors
To test the hypothesis that insulin receptors are involved in the effects of prenatal

T on TH expression in the VTA of adult females, prenatal T-treated females were cotreated with insulin sensitizer rosiglitazone. In addition, we tested the hypothesis that
postnatal treatment with insulin sensitizers rosiglitazone or metformin can reverse the
effects of prenatal T on VTA TH expression.
3.3.1

Insulin sensitizer prevented and reversed effects of prenatal T on TH
expression
Analysis of TH expression was first performed in sections stained for TH using

immunoperoxidase technique and statistical analyses were performed separately to
compare the control (C) and prenatal T-treated (T) females with the groups treated either
prenatally with rosiglitazone (R), postnatally with rosiglitazone (+R), or postnatally with
metformin (+M).
3.3.1.1

Prenatal rosiglitazone treatment
First, we again showed that prenatal T treated females had significantly increased

TH-IR neurons in the VTA (F(1,21=40.57; p<0.001). Prenatal treatment with the insulin
sensitizer rosiglitazone (R) blocked the effects of prenatal T as an interaction of prenatal
T and R treatment was detected (F(1,21)=7.1; p=0.014; Fig. 3.5) and numbers of TH-ir
cells in VTA of prenatal TR females were significantly lower compared to prenatal T
alone-treated females (p=0.036) and similar to control females (C or CR). Prenatal
treatment of R alone had no effect in control females (CR).

57

3.3.1.2

Postnatal rosiglitazone treatment
In addition, postnatal treatment with R (+R) partially reversed the effects of

prenatal T on TH-ir neurons in VTA (Effect of +R: F(1,21)=7.54; p=0.012; and
interaction between prenatal T and +R: F(1,21)=5.1; p=0.035). Post hoc analyses showed
that numbers of TH-ir cells in females treated prenatally with T and postnatally with R
(T+R) were significantly lower compared to females treated prenatally with T alone (T;
p=0.002), but were significantly higher compared to control females treated postnatally
with R alone (C+R; p=0.02; Fig.3.5). Postnatal treatment of R alone in control females
(C+R) did not affect TH-ir as these females did not differ from untreated control females.
3.3.1.3

Postnatal metformin treatment
Finally, postnatal treatment with metformin had similar effects as postnatal

treatment with R and partially reversed the effects of prenatal T. There was a main effect
of metformin (F(1,17)=4.5; p=0.048). Numbers of TH-ir neurons in VTA of prenatal Ttreated females that were treated postnatally with M (T+M) were lower compared to
prenatal T alone (p=0.027), but higher compared to control females treated postnatally
with M (C+M; p=0.004; Fig. 3.5). M treatment alone in control females did not affect
numbers of TH-ir neurons. Together these results suggest that prenatal T acts in part via
reducing sensitivity of the insulin receptor.
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Figure 3.5

Prenatal and postnatal treatments of insulin sensitizers block or reverse
effects of prenatal T on VTA TH expression.

Representative images of VTA TH-ir in control females (A; C), prenatal testosterone (B;
T), prenatal rosiglitazone (C; CR), prenatal testosterone and prenatal rosiglitazone (D;
TR), postnatal rosiglitazone (E; C+R), prenatal testosterone and postnatal rosiglitazone
(F; T+R), postnatal metformin (G; C+M), and prenatal testosterone and postnatal
metformin (H; T+M). Scale bar indicates 50 µm. Graph (E) shows numbers of TH-ir
cells in the VTA of these eight groups: Data are presented as mean ± SEM and *
indicates statistically significant difference from control.
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3.3.2

Expression of insulin receptor in VTA TH neurons
Since insulin receptor sensitizers block or reverse the effects of prenatal T on

VTA TH expression, we next addressed the question if insulin receptors are expressed
specifically in VTA TH neurons. Dual fluorescence showed that IRβ is indeed expressed
in TH-ir in the VTA (Fig. 3.6). In control females, approximately 94% of TH-ir neurons
co-express IRβ. Moreover, the majority of IRβ in the VTA is expressed in TH-ir neurons
(approximately 93%). In contrast, TH-ir neurons in the substantia nigra did not coexpress IRβ (Fig. 3.6). IRβ was also observed in other areas surrounding the VTA,
including the periaqueductal grey, where it was expressed by non-TH-ir neurons (Fig.
3.6).
3.3.3

Effects of prenatal T and rosiglitazone treatment on expression of insulin
receptor in VTA TH neurons
The results thus far suggest that prenatal T may cause alterations in insulin

receptor expression. We hypothesize that prenatal T will cause a reduction in insulin
receptor expression in TH neurons in the VTA; and that this effects is blocked or
reversed by insulin sensitizer treatment. To test these hypotheses, expression of IRβ was
analyzed in the same groups as in 3.1, using dual fluorescent detection of TH and IRβ.
3.3.3.1

Prenatal rosiglitazone treatment
Two Way ANOVA analysis showed overall effects on TH-ir neurons of prenatal

T treatment (F(1,21)=23.02; p<0.001), prenatal R co-treatment (F(1,21)=11.65; p=0.003),
and an interaction (F(1,21)=23.02; p<0.001 (Fig. 3.6). First, we replicated the findings in
3.1, as prenatal T-treated females had more VTA TH-ir neurons compared to control
females (p<0.001) and females co-treated prenatally with T and R (TR) had fewer TH-IR
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neurons compared to prenatal T-treated females (p<0.001). In contrast to the results in
3.1, TR females did not differ in numbers of TH-ir neurons compared to control females
(CR and C+R resp.). Hence, using the method of analysis used here, we detected a
complete block or reversal of the effects of prenatal T by R co-treatment.
Prenatal T and R treatment also altered expression of IRβ (Fig. 3.6). Two Way
ANOVA analysis showed overall effects on IRβ -ir neurons of prenatal T treatment
(F(1,21)=10.84; p=0.003), prenatal R co-treatment (F(1,21)=5.53; p=0.029), and an
interaction (F(1,21)=8.49; p=0.008 (Fig. 3.6). In particular, prenatal T caused an increase
in numbers of IRβ-ir neurons in the VTA compared to control females (p<0.001).
Moreover, prenatal co-treatment with R complete blocked this effect of prenatal T
(p=0.002) and IRβ expression in this group did not differ from controls (CR and C).
However, when the expression of IRβ specifically in TH neurons was analyzed, the
opposite effect of prenatal T was found. Two Way ANOVA analysis showed overall
effects on percentages of TH-ir neurons that co-express IRβ of prenatal T treatment
(F(1,21)= 26.78; p<0.001), prenatal R co-treatment (F(1,21)=23.2; p<0.001), and an
interaction (F(1,21)=9.59; p=0.005 (Fig. 3.6). Prenatal T significantly decreased
expression of IRβ in TH neurons (Figure; p<0.001 compared to control). Prenatal cotreatment with R blocked this effect of prenatal T (Fig. 3.6) as TR females had
significantly higher percentages of TH-ir neurons that expressed IRβ compared to T alone
(p<0.001) and did not differ from control groups (CR and C+R). Prenatal treatment with
R alone had no effects in control groups.
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3.3.3.2

Postnatal rosiglitazone treatment
The effects of postnatal treatment with R were identical to those of prenatal co-

treatment as it completely reversed the effects of prenatal T on IRβ expression in VTA
TH neurons. Postnatal treatment with R reversed the effects of prenatal T on numbers of
TH-ir neurons (F(1,21)=17.15; p<0.001; T+R versus T: p<0.001), on numbers of IRβ-ir
neurons (F(1,21)=10.12; p=0.005; T+R versus T: p=0.001), and on percentages of TH-ir
neurons co-expressing IRβ (F(1,21)=11.29; p=0.003; T+R versus T: p=0.002; Fig. 3.6).
Postnatal treatment with R had no effects in control groups.
Together, these findings support the hypothesis that prenatal T causes reduction of
insulin receptor expression in VTA TH neurons. Moreover, these results suggest that
treatment with rosiglitazone may block or reverse the effects of prenatal T by restoring
the expression of insulin receptors in TH neurons.
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Figure 3.6

Prenatal and postnatal treatments of insulin sensitizers block or reverse
effects of prenatal T on insulin receptor expression in VTA TH cells.

The first row: representative images of a VTA section immunostained for IRβ (red; A) and TH
(green; B). Right panel (C) is a merged image illustrating the high degree of co-localization of
TH-ir neurons and IRβ. Second row: Representative images of the SN showing minimal
expression of IRβ (red; D) in an area adjacent to the VTA with high TH (green; E). Right panel
(F) is a merged image showing minimal co-expression of IRβ/TH in the SN. Third row:
Representative images of an area in the periaqueductal grey, dorsal to the VTA, showing an area
with IRβ (red; G) but minimal TH (green; H) and thus no co-expression (right panel; I) Scale bar
indicates 50 µm.
Graphs show numbers of VTA TH-ir cells (J), VTA IRβ-ir cells (K), and percent of TH-ir cells
that co-express IRβ (L) in the VTA, in control females (C), and females treated with prenatal
testosterone (T), prenatal rosiglitazone (CR), prenatal testosterone and prenatal rosiglitazone (D;
TR), postnatal rosiglitazone (C+R), or prenatal testosterone and postnatal rosiglitazone (T+R).
Data are presented as mean ± SEM and * indicates statistically significant difference from
control.
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3.3.4

Effects of prenatal T and rosiglitazone treatment on expression of androgen
receptor in VTA TH neurons
Our findings thus far have determined that prenatal T affects both expression of

AR and IRβ in VTA TH neurons. Therefore, it is possible that there may be interactions
between these two receptors. To further address this hypothesis, AR expression was
analyzed in the same groups used above, treated prenatally or postnatally with R, or
postnatally with M.
3.3.4.1

Prenatal rosiglitazone treatment
Two way ANOVA analysis of AR expression in sections stained with

immunoperoxidase technique showed an overall effect of prenatal T (F(1,22)=74.85;
p<0.001), of prenatal R (F(1,22)=10.14; p=0.004) and an interaction between the two
factors (F(1,22)=8.063; p=0.01) (Fig. 3.7). Post hoc analyses showed that prenatal T
increased numbers of AR-ir in the VTA (p<0.001 compared to C), as we reported above
in study 2. Prenatal co-treatment with R partially blocked the effects of prenatal T: TR
females had significantly fewer number of AR-ir neurons compared to prenatal T alone
(p<0.001), but significantly more compared to CR females (p<0.001). R treatment in
control groups had no effect on numbers of AR-ir cells.
3.3.4.2

Postnatal rosiglitazone treatment
The effects of postnatal treatment on AR expression in VTA were similar to those

of the prenatal treatment. There was no significant overall effect of postnatal R treatment,
but a significant interaction between prenatal T and postnatal R was detected
(F(1,16)=7.03; p=0.017). Numbers of AR-ir neurons were lower in T+M females
compared to prenatal T alone (p=0.004), but higher compared to C+R (p<0.001; Fig. 3.7).
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3.3.4.3

Postnatal metformin treatment
Finally, postnatal treatment with metformin mirrored the effects of postnatal R

treatment. There was no significant overall effect of postnatal M treatment, but a
significant interaction between prenatal T and postnatal M (F(1,23)=10.73;
p=0.003).Specifically, numbers of AR-ir neurons were lower in T+M females compared
to prenatal T alone (p=0.016), but higher compared to C+M (p=0.007; Fig. 3.7).

Figure 3.7

Prenatal and postnatal treatments of insulin sensitizers block or reverse
effects of prenatal T on androgen receptor expression in VTA.

Graph shows numbers of AR-ir cells in the VTA in control females (C), prenatal
testosterone (T), prenatal rosiglitazone (CR), prenatal testosterone and prenatal
rosiglitazone (TR), postnatal rosiglitazone (C+R), prenatal testosterone and postnatal
rosiglitazone (T+R), postnatal metformin (C+M), and prenatal testosterone and postnatal
metformin (T+M). Data are presented as mean ± SEM. * indicates statistically
significant difference from the appropriate control. # indicates statistically significant
difference from prenatal testosterone-treated animals.
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CHAPTER IV
DISCUSSION

4.1

Study 1: Stereology
The first aim of this study was to determine whether sex differences in the

numbers of neurons expressing TH in the VTA was also associated with an overall
increase in numbers of neurons and the size or volume of the VTA . Moreover, I
examined if the effects of prenatal exposure to T affected numbers of neurons and
volume of VTA in females. In this experiment, unbiased stereology was utilized.
Stereology is an unbiased method of analysis and is similar to three-dimensional serial
reconstruction (173) ,and the entire volume for the area of analysis is obtainable,
providing data to determine the volume of VTA between treatment groups. This method
of cell counting was also used to further confirm the changes we determined in the
numbers of TH-ir cells using other cell counting methods.
Stereological analyses showed that TH-ir neuron numbers were significantly
increased in prenatal T females and control males when compared to control females,
confirming our previous findings. Previous studies in rodents have examined sex
differences in numbers of VTA TH-ir neurons, but have not examined effects of prenatal
exposure to T. Moreover, results in rodents are different from those obtained in sheep.
Female rats have a significantly higher number of DA cells in the VTA compared to
males (146), while in other studies, no differences were detected.
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The increase in TH-ir cells in males or in females exposed to prenatal T could be
caused by heightened neuron survival (147) (146,150). Therefore, we determined sex
differences and the effects of prenatal T on other non-TH-ir cells in the VTA, as well as
total volume. These parameters were not affected by sex or prenatal T, suggesting that
the effects of sex or prenatal T are specific to TH neurons and not generalized, hence
unlikely due to neuronal survival. Similar findings of a lack of change in VTA non-TH-ir
cells have been reported in rats and non-human primates (150) (151) (174). In mice, data
have been somewhat controversial. In 2013, Campi et al. determined no sex differences
of VTA volume of California mice; however, McAuthor et al. (2007) found that overall,
females had a significantly larger VTA when measured by volume (175) (146).
Together, these findings demonstrate that there is an increase in numbers of TH-ir
cells in the VTA of males and prenatal T-treated females. We hypothesize that this
increase in cell number reflects an increase in TH protein expression. This is supported
by our previous findings that there is an increased density of TH immunoreactivity within
the VTA neurons in males and prenatal T-treated females, i.e. the staining is significantly
darker. This increased density of immunoreactivity is typically caused by increased
protein expression. However, to test this hypothesis conclusively, future studies are
required to conduct quantitative analyses of protein expression, such as western blot
analyses. Finally, increased TH protein is assumed to be indicative of increased dopamine
synthesis, as TH is the rate-limiting enzyme. But again, future studies are needed to
further test this assumption, For example, micro dialysis experiments can be used to
measure extracellular release of dopamine within the VTA or in other brain areas that
receive inputs from the VTA dopamine neurons.
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4.2

Study 2: Prenatal T influences VTA TH neurons via androgen receptors
Our laboratory previously showed that prenatal T treatment between days 30 – 90

of gestation increased the number of TH-ir cells in adult female ewes. Moreover, this
effect was mimicked by prenatal treatment with DHT, but not E2, suggesting that
prenatal T may exert it’s effects via activation of androgenic receptors and not estrogenic
receptors. This hypothesis was tested and confirmed in my experiments in Study 2. In
particular, I demonstrated that prenatal co-treatment of T with androgen receptor blocker
flutamide completely blocked the effects of prenatal T treatment on the increase in TH
expression in the VTA. Therefore, prenatal T excess causes increased expression of TH
in VTA of adult ewes by activating AR during the prenatal period.
PCOS women have hyperandrogensim, which is evidenced by increased plasma
levels of T (see Introduction). However, in sheep, and many other animal models, levels
of T are extremely variable and difficult to detect in plasma. Therefore, in the prenatal Tsheep model utilized in or studies, we have previously been unable to demonstrate
hyperandrogenism based on plasma levels of T. Instead, our laboratory has demonstrated
that the numerous brain areas in the hypothalamus, preoptic area (Cernea et al.,
unpublished), and VTA (Brown et al., unpublished) have increased expression levels of
AR. Since increased AR expression can be caused by increased ligand binding to the
receptor, i.e. increased levels of androgens, these results have been indicative of a
functional hyperandrogenism in prenatal T-treated ewes.
My studies further investigated the expression of AR in the VTA and the effects
of prenatal T treatment on AR expression. I showed that AR was predominantly
expressed in TH neurons and that prenatal T significantly increased AR expression in TH
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neurons, These results suggest that prenatal T causes increased sensitivity of the VTA TH
neurons to circulating androgens. Moreover, I showed that these effects of prenatal T on
adult AR expression were caused by prenatal activation of AR, as the effects of prenatal
T were blocked by co-treatment with flutamide.
Three main questions have emerged from my experiments in Study 2 that require
further investigation. The first question relates to the mechanisms by which excess
prenatal T influences adult levels of AR expression. It is possible that prenatal T causes
epigenetic alterations of the AR gene (176). It is also possible that prenatal T does not
cause alterations in expression of AR per se, but rather causes increased production of
androgens. One source of androgen production is the ovary. However, all animals in our
studies received a bilateral ovariectomy and estradiol implants to eliminate potential
differences in the estrogen and androgen levels in all experimental groups. Thus,
production of androgens by the ovary cannot have been a contributing factor in our
studies. A second source of androgens is the adrenal glands. It is currently unknown if
prenatal T-treatment has effects on adrenal gland production of androgens, and thus
future research will be needed to investigate this possibility. Our laboratory does have
unpublished data suggesting that there are no differences in circulating levels of
corticosterone, another hormone produced by the adrenal gland, or increased responses to
stress (Lee et al., unpublished).
The second question relates to the mechanisms by which increased AR expression
or activation may cause alterations in TH expression. There is evidence that AR
transactivates TH promoter function and gene expression (177). Therefore, increased AR
in the female VTA could be increasing the production of TH by up-regulating the TH
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promoter function in a ligand dependent manner and further studies are needed to test this
hypothesis.
A final question is whether the effects of prenatal T on increased TH and AR
occur immediately and are observed prior to puberty, or are further dependent on the
activational effects of steroid hormones. Studies to examine effects of prenatal T on TH
and AR expression in lambs, and prepubertal ages; or by manipulating the activational
effects of steroid hormones are required to further address this final hypothesis.
4.3

Study 3: Prenatal T influences VTA TH via insulin receptors
The final hypothesis evaluated in this thesis was that the effects of prenatal T on

TH expression in the VTA of adult ewes are partially caused by insulin insensitivity early
in life. Thus, we hypothesize that effects of prenatal T can be blocked or reversed by
insulin receptor sensitizer treatment either during prenatal life or by postnatal treatment.
Treatment with insulin sensitizers have been shown to be somewhat effective in treating
anovulation, insulin resistance, and hyperandrogenism in PCOS women (See
Introduction).
Indeed, prenatal co-treatment with rosiglitazone partially blocked the effects of T
on TH expression, and postnatal treatment with rosiglitazone or metformin partially
reversed the effects of prenatal T on TH expression. Thus, these findings confirmed the
hypothesis that effects of prenatal T are caused in part by insulin receptor insensitivity.
Maternal increases in circulating insulin levels associated with T treatment (Salloum, B.
and Padmanabhan, V., unpublished data) may contribute to this insulin insensitivity in
the fetus.
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In addition, I demonstrated that VTA TH neurons express insulin receptors and
that prenatal T caused decreased expression of insulin receptors within these TH neurons.
Hence, prenatal T treatment causes insensitivity to insulin by down regulation of insulin
receptor expression within TH neurons.
Also possible is the exposure of the fetus to high levels of T and maternal insulin
may reprogram organization of the reward system via a pathway that is mediated by both
influences.
Finally, postnatal treatment with insulin sensitizers in women with PCOS has
beneficiary effects on hyperandrogensism. Therefore, we hypothesized that prenatal or
postnatal treatments with insulin sensitizers would also block or reverse the effects of
prenatal T on androgen receptors. Indeed, the findings support the hypothesis as AR
expression was partially blocked or reversed by rosiglitazone or metformin treatment.
The findings of this study implicate both AR and IR in the mediation of TH expression in
the VTA. suggesting that insulin and androgen signaling may act synergistically to cause
the long-term changes in this cell population. Therefore, insulin may intensify the effect
of prenatal testosterone.
4.4

Behavioral Studies
One main remaining question that has not yet been discussed is whether the

prenatal and postnatal treatments that blocked or reversed the effects of prenatal T on TH,
AR, and IR expression in the VTA, also blocked or reversed the effects of prenatal T on
reproductive and food-related behaviors. Even though this question is outside the scope
of my thesis, behavioral data were collected and analyzed by our laboratory on the
animals used in Study 3 of this thesis and are briefly summarized here. In addition, data
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from animals treated prenatally or postnatally with flutamide (but not used in this thesis)
were collected and analyzed.
4.5

Sexual behavior
Prenatal T caused alterations in sexual behavior of the adult ewes. Sexual

behavior consists of appetitive and consummatory behaviors, both of which are highly
sexually dimorphic. Appetitive behaviors are behaviors associated with the approach of
the sexual partner. Female-typical behaviors include approach behavior, tail and ear
wiggling; while male-typical behaviors include pawing, tongue thrusting, nudging, and
calling. Consummatory behaviors are behaviors associated with the actual act of mating.
Female-typical behaviors include standing and being mounted; while male-typical
behaviors including mounting and thrusting. Prenatal T-treatment affects both aspects of
sexual behavior and prenatal T-treated females displayed significantly less female-typical
appetitive and consummatory sexual behaviors and significantly more male-typical
behaviors. Prenatal treatment with flutamide, but not rosiglitazone, partially blocked the
effects of prenatal T: the effects on consummatory, but not appetitive behaviors were
blocked. Postnatal treatment with flutamide had the same effect and partially reversed the
effects of prenatal T. These results suggest that the effects of prenatal T on
consummatory aspects of sexual behavior are mediated by activation and actions on AR,
but not IR. Moreover, the effects of prenatal T on appetitive sexual behavior appears to
be mediated by an entirely different mechanism, and may be involved activation of
estrogen receptors.
Therefore, it is possible that prenatal co-treatment with flutamide blocked the
effects of prenatal T on sexual behavior by blocking the effects on VTA TH expression.
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However, the increased TH expression in the VTA following prenatal T treatment does
not appear to be the sole contributor to the expression of sexual behavior, as insulin
sensitizer treatment did reverse or block the effects of prenatal TH on VTA TH
expression, without blocking or reversing the effects of prenatal T on sexual behavior.
4.6

Food reward-related behavior
Prenatal T also affected the reward seeking behavior associated with palatable

food. This was assessed using a paradigm called conditioned place preference, which is a
well-documented and utilized paradigm to measure reward seeking behavior associated
with natural and drug rewards (178-180). Prenatal T significantly increased the
conditioned place preference for palatable food, even in females that were fed and sated
prior to this reward test. Interestingly, both prenatal and postnatal treatments with either
flutamide or rosiglitazone completely blocked or reversed the effect of prenatal T on food
reward-seeking behavior. Together with my findings that treatments with flutamide and
rosiglitazone block or reverse the effects of prenatal T on TH expression in the VTA,
these results suggest that the VTA TH neurons indeed may play a pivotal role in the food
reward and the effects of prenatal T on this behavior. Further studies may investigate
alterations in dopamine receptors expression or activation in areas that receive
dopaminergic inputs from the VTA TH neurons, or studies using dopamine receptor
antagonism could be explored to reverse the effects of prenatal T on food reward seeking
behavior.
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4.7

Conclusion
In summary, the sets of studies presented in my thesis demonstrated mechanisms

by which prenatal exposure to excess T causes long term alterations in expression of
dopamine, androgen, and insulin receptors in the adult ewe VTA. Moreover, I was able to
show that insulin sensitizer or androgen receptor blockade, currently used treatments in
women with PCOS, indeed partially or completely reverse effects of prenatal T on this
mesolimbic pathway.
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